Referred to the House Committee on Energy and Commerce.
This bill directs the Department of Health and Human Services (HHS) and the National Institutes of Health (NIH) to expand, coordinate, and support research on uterine fibroids, including authorization of $30 million per year for research from FY2026–2030. It requires HHS to establish or expand a Medicaid/CHIP research database and to report to Congress within two years on federal and state expenditures for fibroid treatment under those programs.
Degree of enthusiasm for federal spending: liberals strongly favor the investment; conservatives worry about open-ended spending and federal overreach.
Relative to its intended legislative type, this bill is a substantive policy measure that establishes and authorizes federal action on uterine fibroid research, data collection, and education.
This bill directs the Department of Health and Human Services (HHS) and the National Institutes of Health (NIH) to expand, coordinate, and support research on uterine fibroids, including authorization of $30 million per year for research from FY2026–2030.
It requires HHS to establish or expand a Medicaid/CHIP research database and to report to Congress within two years on federal and state expenditures for fibroid treatment under those programs.
The bill instructs HHS to develop public education materials about fibroids (including incidence, risk among minority individuals, and non-hysterectomy treatment options) and to disseminate evidence-based information to health care providers in consultation with medical societies.
Content is non‑controversial, administratively straight‑forward, and limited in scope, which increases prospects for bipartisan support. Major obstacles are fiscal—this is an authorization that requires appropriations—and the Senate’s procedural barriers. The unspecified funding language for education and reliance on appropriations introduce uncertainty that reduces likelihood relative to truly budget‑neutral or technical fixes.
Relative to its intended legislative type, this bill is a substantive policy measure that establishes and authorizes federal action on uterine fibroid research, data collection, and education. It clearly defines the problem and integrates actions into existing legal structures, and it includes a specific multi‑year research appropriation. Operational specifics, protections for data collection, precise funding for non‑research activities, and detailed accountability metrics are limited or absent.
Degree of enthusiasm for federal spending: liberals strongly favor the investment; conservatives worry about open-ended spending and federal overreach.
These are examples from the analysis, not a ranked list of the most-affected groups.
Degree of enthusiasm for federal spending: liberals strongly favor the investment; conservatives worry about open-ended spending and federal overreach.
A liberal/left-leaning observer would likely view this bill positively as a targeted federal response to a common, under-researched women’s health condition that disproportionately harms people of color.
They would welcome the dedicated NIH funding, the focus on disparities and minority populations, and the push for fertility-friendly, minimally invasive treatments and better patient education.
They would see the Medicaid/CHIP data work as an important step toward documenting access gaps and cost burdens that fall on low-income and racially marginalized communities.
A centrist/moderate reader would generally support the bill as a focused, evidence-building approach to an important public-health issue with clear cost and quality implications.
They would appreciate the relatively modest, time-limited research appropriation and the emphasis on data collection to inform future policy.
However, they would want clarity on total costs for the education/provider outreach components and on how outcomes will be measured and overseen.
A mainstream conservative observer would assess the bill pragmatically: they may support basic research and provider education on a common medical condition but be cautious about new federal spending, open-ended authorizations, and bureaucratic growth.
They would likely welcome non-partisan goals like improving evidence and reducing unnecessary surgeries, but question the need for federal involvement in education and the use of 'such sums as may be necessary.' Concerns would also focus on fiscal restraint, federal overreach into state-managed Medicaid data, and ensuring the program does not become a vehicle for broader reproductive-policy objectives.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Content is non‑controversial, administratively straight‑forward, and limited in scope, which increases prospects for bipartisan support. Major obstacles are fiscal—this is an authorization that requires appropriations—and the Senate’s procedural barriers. The unspecified funding language for education and reliance on appropriations introduce uncertainty that reduces likelihood relative to truly budget‑neutral or technical fixes.
The bill has not accumulated any surfaced votes yet.
Degree of enthusiasm for federal spending: liberals strongly favor the investment; conservatives worry about open-ended spending and federa…
Content is non‑controversial, administratively straight‑forward, and limited in scope, which increases prospects for bipartisan support. Ma…
Relative to its intended legislative type, this bill is a substantive policy measure that establishes and authorizes federal action on uterine fibroid research, data collection, and education. It clearly defines the pro…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.